Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1126

1.

Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party.

El-Cheikh J, Labopin M, Al-Chami F, Bazarbachi A, Angelucci E, Santarone S, Bonifazi F, Carella AM, Castagna L, Bruno B, Iori AP, La Nasa G, Savani B, Nagler A, Mohty M.

Clin Lymphoma Myeloma Leuk. 2020 Jan 27. pii: S2152-2650(20)30044-6. doi: 10.1016/j.clml.2020.01.007. [Epub ahead of print]

PMID:
32081702
2.

LDH and renal function are prognostic factors for long-term outcomes of multiple myeloma patients undergoing allogeneic hematopoietic stem cell.

Shouval R, Teper O, Fein JA, Danylesko I, Shem Tov N, Yerushalmi R, Avigdor A, Vasilev E, Magen H, Nagler A, Shimoni A.

Bone Marrow Transplant. 2020 Feb 17. doi: 10.1038/s41409-020-0829-1. [Epub ahead of print]

PMID:
32066863
3.

Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission.

Díaz-Beyá M, Labopin M, Maertens J, Alijurf M, Passweg J, Dietrich B, Schouten H, Socié G, Schaap N, Schwerdtfeger R, Volin L, Michallet M, Polge E, Sierra J, Mohty M, Esteve J, Nagler A; Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).

Br J Haematol. 2020 Feb 5. doi: 10.1111/bjh.16433. [Epub ahead of print]

PMID:
32020596
4.

Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.

Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, Ciceri F, Cornelissen J, Malladi R, Duarte RF, Giebel S, Greinix H, Holler E, Lawitschka A, Mielke S, Mohty M, Arat M, Nagler A, Passweg J, Schoemans H, Socié G, Solano C, Vrhovac R, Zeiser R, Kröger N, Basak GW.

Lancet Haematol. 2020 Feb;7(2):e157-e167. doi: 10.1016/S2352-3026(19)30256-X. Review.

PMID:
32004485
5.

Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients.

Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, Socié G, Platzbecker U, Beelen D, Milpied N, Cornelissen JJ, Ganser A, Huynh A, Griskevicius L, Giebel S, Brissot E, Malard F, Esteve J, Peric Z, Baron F, Ruggeri A, Schmid C, Gilleece M, Gorin NC, Lanza F, Shouval R, Versluis J, Bug G, Fløisand Y, Ciceri F, Sanz J, Bazarbachi A, Nagler A, Mohty M.

Bone Marrow Transplant. 2020 Jan 29. doi: 10.1038/s41409-020-0803-y. [Epub ahead of print]

PMID:
31996792
6.

Remission of acute myeloid leukemia with t(8;21) following CD19 CAR T-cells.

Danylesko I, Jacoby E, Yerushalmi R, Shem-Tov N, Besser MJ, Vernitsky H, Marcu-Malina V, Shimoni A, Avigdor A, Nagler A.

Leukemia. 2020 Jan 24. doi: 10.1038/s41375-020-0719-y. [Epub ahead of print] No abstract available.

PMID:
31980731
7.

Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel.

Bonifazi F, Rubio MT, Bacigalupo A, Boelens JJ, Finke J, Greinix H, Mohty M, Nagler A, Passweg J, Rambaldi A, Socie G, Solano C, Walker I, Barosi G, Kröger N.

Bone Marrow Transplant. 2020 Jan 22. doi: 10.1038/s41409-020-0792-x. [Epub ahead of print]

PMID:
31969678
8.

PAR1 Expression Predicts Clinical G-CSF CD34+ HSPC Mobilization and Repopulation Potential in Transplanted Patients.

Nevo N, Zuckerman T, Gur-Cohen S, Kollet O, Avemaria F, Shpall EJ, Mendt MC, Nagler A, Brenner B, Ben Arush M, Lapidot T.

Hemasphere. 2019 Aug 20;3(5):e288. doi: 10.1097/HS9.0000000000000288. eCollection 2019 Oct. No abstract available.

9.

Decision-analytic modeling as a tool for selecting optimal therapy incorporating hematopoietic stem cell transplantation in patients with hematological malignancy.

Fuji S, Nagler A, Mohty M, Savani B, Shouval R.

Bone Marrow Transplant. 2020 Jan 13. doi: 10.1038/s41409-020-0784-x. [Epub ahead of print] Review.

PMID:
31932655
10.

Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party.

Bazarbachi A, Labopin M, Angelucci E, Gülbas Z, Ozdogu H, Arat M, de Rosa L, Pastano R, Pioltelli P, Montserrat R, Martino M, Ciceri F, Koç Y, Socié G, Blaise D, Herrera C, Chalandon Y, Bernasconi P, Marotta G, Castagna L, McDonald A, Visani G, Carluccio P, Vitek A, Simand C, Afanasyev B, Rösler W, Diez-Martin JL, Nagler A, Brissot E, Giebel S, Mohty M.

Biol Blood Marrow Transplant. 2020 Jan 9. pii: S1083-8791(20)30013-6. doi: 10.1016/j.bbmt.2020.01.003. [Epub ahead of print]

PMID:
31926364
11.

Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.

Danylesko I, Chowers G, Shouval R, Besser MJ, Jacoby E, Shimoni A, Nagler A, Avigdor A.

Curr Res Transl Med. 2020 Jan;68(1):17-22. doi: 10.1016/j.retram.2019.12.001. Epub 2019 Dec 25.

PMID:
31882377
12.

The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation.

Poiré X, Labopin M, Polge E, Volin L, Finke J, Ganser A, Blaise D, Yakoub-Agha I, Beelen D, Forcade E, Lioure B, Socié G, Niederwieser D, Labussière-Wallet H, Maertens J, Cornelissen J, Craddock C, Mohty M, Esteve J, Nagler A.

Am J Hematol. 2020 Mar;95(3):282-294. doi: 10.1002/ajh.25714. Epub 2020 Jan 17.

PMID:
31876307
13.

Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.

Dreyling M, Santoro A, Mollica L, Leppä S, Follows G, Lenz G, Kim WS, Nagler A, Dimou M, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Munoz J, Rodrigues L, Hiemeyer F, Miriyala A, Garcia-Vargas J, Childs BH, Zinzani PL.

Am J Hematol. 2019 Dec 23. doi: 10.1002/ajh.25711. [Epub ahead of print]

PMID:
31868245
14.

What's in a Name? Role Clarity Goes Well Beyond a Simple Title.

Turner DA, Rehder KJ, Nagler A, Aucoin J, Edwards P, Kuhn C.

J Patient Exp. 2019 Dec;6(4):325-328. doi: 10.1177/2374373518803615. Epub 2018 Oct 10.

15.
16.

Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

Passweg JR, Labopin M, Christopeit M, Cornelissen J, Pabst T, Socié G, Russel N, Yakoub-Agha I, Blaise D, Gedde-Dahl T, Labussière-Wallet H, Malladi R, Forcade E, Maury S, Polge E, Lanza F, Gorin NC, Mohty M, Nagler A.

Biol Blood Marrow Transplant. 2019 Nov 21. pii: S1083-8791(19)30788-8. doi: 10.1016/j.bbmt.2019.11.021. [Epub ahead of print]

PMID:
31759159
17.

Correction: Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).

Snowden JA, Saccardi R, Orchard K, Ljungman P, Duarte RF, Labopin M, McGrath E, Brook N, de Elvira CR, Gordon D, Poirel HA, Ayuk F, Beguin Y, Bonifazi F, Gratwohl A, Milpied N, Moore J, Passweg J, Rizzo JD, Spellman SR, Sierra J, Solano C, Sanchez-Guijo F, Worel N, Gusi A, Adams G, Balan T, Baldomero H, Macq G, Marry E, Mesnil F, Oldani E, Pearce R, Perry J, Raus N, Schanz U, Tran S, Wilcox L, Basak GW, Chabannon C, Corbacioglu S, Dolstra H, Kuball J, Mohty M, Lankester A, Montoto S, Nagler A, Styczynski J, Yakoub-Agha I, de Latour RP, Kroeger N, Brand R, de Wreede LC, van Zwet E, Putter H.

Bone Marrow Transplant. 2019 Nov 21. doi: 10.1038/s41409-019-0740-9. [Epub ahead of print]

PMID:
31754251
18.

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).

Yakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, Corbacioglu S, Duarte RF, Einsele H, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Robinson S, Saccardi R, Sanchez-Guijo F, Snowden JA, Srour M, Styczynski J, Urbano-Ispizua A, Hayden PJ, Kröger N.

Haematologica. 2020 Jan 31;105(2):297-316. doi: 10.3324/haematol.2019.229781. Print 2020.

19.

Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT.

Shimoni A, Labopin M, Finke J, Ciceri F, Deconinck E, Kröger N, Gramatzki M, Stelljes M, Blaise D, Stoelzel F, Chevallier P, Holler E, Fegueux N, Mohty M, Nagler A.

Blood Cancer J. 2019 Nov 18;9(12):88. doi: 10.1038/s41408-019-0251-3.

20.

The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation.

Nagler A, Dholaria B, Labopin M, Socie G, Huynh A, Itälä-Remes M, Deconinck E, Yakoub-Agha I, Cahn JY, Bourhis JH, Labussière-Wallet H, Chantepie S, Esteve J, Savani B, Mohty M.

Leukemia. 2019 Nov 14. doi: 10.1038/s41375-019-0631-5. [Epub ahead of print]

PMID:
31728052
21.

Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas.

Foss FM, Horwitz SM, Civallero M, Bellei M, Marcheselli L, Kim WS, Cabrera ME, Dlouhy I, Nagler A, Advani RH, Pesce EA, Ko YH, Montoto S, Chiattone C, Moskowitz A, Spina M, Cesaretti M, Biasoli I, Federico M.

Am J Hematol. 2020 Feb;95(2):151-155. doi: 10.1002/ajh.25674. Epub 2019 Nov 25.

PMID:
31709579
22.

Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia.

Gratwohl A, Duarte R, Snowden JA, van Biezen A, Baldomero H, Apperley J, Cornelissen J, Greinix HT, Grath EM, Mohty M, Kroeger N, Nagler A, Niederwieser D, Putter H, Brand R; Joint Accreditation Committee JACIE.

EClinicalMedicine. 2019 Aug 9;15:33-41. doi: 10.1016/j.eclinm.2019.07.019. eCollection 2019 Oct.

23.

CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.

Mohty M, Gautier J, Malard F, Aljurf M, Bazarbachi A, Chabannon C, Kharfan-Dabaja MA, Savani BN, Huang H, Kenderian S, Nagler A, Perales MA.

Leukemia. 2019 Dec;33(12):2767-2778. doi: 10.1038/s41375-019-0615-5. Epub 2019 Nov 5. Review.

PMID:
31690821
24.

Safety, Resistance, and Efficacy Results from a Phase IIIb Study of Conventional- and Double-Dose Oseltamivir Regimens for Treatment of Influenza in Immunocompromised Patients.

Mitha E, Krivan G, Jacobs F, Nagler A, Alrabaa S, Mykietiuk A, Kenwright A, Le Pogam S, Clinch B, Vareikiene L.

Infect Dis Ther. 2019 Dec;8(4):613-626. doi: 10.1007/s40121-019-00271-8. Epub 2019 Oct 30.

25.

Amphiregulin contributes to airway remodeling in chronic allograft dysfunction after lung transplantation.

Todd JL, Kelly FL, Nagler A, Banner K, Pavlisko EN, Belperio JA, Brass D, Weigt SS, Palmer SM.

Am J Transplant. 2019 Oct 30. doi: 10.1111/ajt.15667. [Epub ahead of print]

PMID:
31665560
26.

Isotretinoin, Patient Safety, and Patient-Centered Care-Time to Reform iPLEDGE.

Barbieri JS, Frieden IJ, Nagler AR.

JAMA Dermatol. 2019 Oct 30. doi: 10.1001/jamadermatol.2019.3270. [Epub ahead of print] No abstract available.

PMID:
31664426
27.
28.

Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.

Pavlů J, Labopin M, Niittyvuopio R, Socié G, Yakoub-Agha I, Wu D, Remenyi P, Passweg J, Beelen DW, Aljurf M, Kröger N, Labussière-Wallet H, Perić Z, Giebel S, Nagler A, Mohty M.

J Hematol Oncol. 2019 Oct 23;12(1):108. doi: 10.1186/s13045-019-0790-x.

29.

Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT.

Heinicke T, Labopin M, Polge E, Niederwieser D, Platzbecker U, Sengelov H, Choi G, Cornelissen J, Blaise D, Kuball J, van Gorkom G, Schaap N, Potter V, Paul F, Savani BN, Nagler A, Mohty M.

Bone Marrow Transplant. 2019 Oct 23. doi: 10.1038/s41409-019-0720-0. [Epub ahead of print]

PMID:
31645668
30.

Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).

Snowden JA, Saccardi R, Orchard K, Ljungman P, Duarte RF, Labopin M, McGrath E, Brook N, de Elvira CR, Gordon D, Poirel HA, Ayuk F, Beguin Y, Bonifazi F, Gratwohl A, Milpied N, Moore J, Passweg J, Rizzo JD, Spellman SR, Sierra J, Solano C, Sanchez-Guijo F, Worel N, Gusi A, Adams G, Balan T, Baldomero H, Macq G, Marry E, Mesnil F, Oldani E, Pearce R, Perry J, Raus N, Schanz U, Tran S, Wilcox L, Basak GW, Chabannon C, Corbacioglu S, Dolstra H, Kuball J, Mohty M, Lankester A, Montoto S, Nagler A, Styczynski J, Yakoub-Agha I, de Latour RP, Kroeger N, Brand R, de Wreede LC, van Zwet E, Putter H.

Bone Marrow Transplant. 2019 Oct 21. doi: 10.1038/s41409-019-0718-7. [Epub ahead of print] Erratum in: Bone Marrow Transplant. 2019 Nov 21;:.

PMID:
31636397
31.

Graft-versus-host disease and graft-versus-leukaemia effects in secondary acute myeloid leukaemia: a retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT.

Baron F, Labopin M, Savani BN, Beohou E, Niederwieser D, Eder M, Potter V, Kröger N, Beelen D, Socié G, Itälä-Remes M, Bornhäuser M, Mohty M, Nagler A.

Br J Haematol. 2020 Feb;188(3):428-437. doi: 10.1111/bjh.16185. Epub 2019 Oct 14.

PMID:
31612473
32.

Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group.

Mohty M, Malard F, Abecasis M, Aerts E, Alaskar AS, Aljurf M, Arat M, Bader P, Baron F, Basak G, Bazarbachi A, Blaise D, Ciceri F, Corbacioglu S, Dalle JH, Dignan F, Fukuda T, Huynh A, Kuball J, Lachance S, Lazarus H, Masszi T, Michallet M, Nagler A, NiChonghaile M, Okamoto S, Pagliuca A, Peters C, Petersen FB, Richardson PG, Ruutu T, Saber W, Savani BN, Soiffer R, Styczynski J, Wallhult E, Yakoub-Agha I, Duarte RF, Carreras E.

Bone Marrow Transplant. 2019 Oct 1. doi: 10.1038/s41409-019-0705-z. [Epub ahead of print] No abstract available.

PMID:
31576023
33.

Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party.

Bazarbachi AH, Al Hamed R, Labopin M, Afanasyev B, Hamladji RM, Beelen D, Eder M, Scheid C, Wu D, Bunjes D, Stepensky P, Tischer J, Kröger N, Peric Z, Aljurf M, Giebel S, Nagler A, Mohty M.

Bone Marrow Transplant. 2019 Sep 27. doi: 10.1038/s41409-019-0702-2. [Epub ahead of print]

PMID:
31562398
34.

A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma.

Nagler A, Vredevoogd DW, Alon M, Cheng PF, Trabish S, Kalaora S, Arafeh R, Goldin V, Levesque MP, Peeper DS, Samuels Y.

Pigment Cell Melanoma Res. 2020 Mar;33(2):334-344. doi: 10.1111/pcmr.12825. Epub 2019 Oct 10.

PMID:
31549767
35.

Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT.

Dholaria B, Savani BN, Labopin M, Luznik L, Ruggeri A, Mielke S, Al Malki MM, Kongtim P, Fuchs E, Huang XJ, Locatelli F, Aversa F, Castagna L, Bacigalupo A, Martelli M, Blaise D, Ben Soussan P, Arnault Y, Handgretinger R, Roy DC, O'Donnell P, Bashey A, Solomon S, Romee R, Lewalle P, Gayoso J, Maschan M, Lazarus HM, Ballen K, Giebel S, Baron F, Ciceri F, Esteve J, Gorin NC, Spyridonidis A, Schmid C, Ciurea SO, Nagler A, Mohty M.

Haematologica. 2020 Jan;105(1):47-58. doi: 10.3324/haematol.2019.219790. Epub 2019 Sep 19.

36.

Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study.

Gatwood KS, Labopin M, Savani BN, Finke J, Socie G, Beelen D, Yakoub-Agha I, Chevallier P, Ganser A, Blaise D, Milpied N, Bruno L, Mailhol A, Mohty M, Nagler A.

Bone Marrow Transplant. 2020 Jan;55(1):224-232. doi: 10.1038/s41409-019-0673-3. Epub 2019 Sep 16.

PMID:
31527819
37.

Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis.

Shouval R, Fein JA, Labopin M, Kröger N, Duarte RF, Bader P, Chabannon C, Kuball J, Basak GW, Dufour C, Galimard JE, Polge E, Lankester A, Montoto S, Snowden JA, Styczynski J, Yakoub-Agha I, Mohty M, Nagler A.

Lancet Haematol. 2019 Nov;6(11):e573-e584. doi: 10.1016/S2352-3026(19)30158-9. Epub 2019 Aug 30.

PMID:
31477550
38.

Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis.

Shouval R, Vega Y, Fein JA, Danylesko I, Shem Tov N, Yerushalmi R, Sobas M, Czyż A, Nagler A, Shimoni A.

Bone Marrow Transplant. 2020 Jan;55(1):147-156. doi: 10.1038/s41409-019-0653-7. Epub 2019 Aug 28.

PMID:
31462682
39.

Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors.

Styczyński J, Tridello G, Koster L, Iacobelli S, van Biezen A, van der Werf S, Mikulska M, Gil L, Cordonnier C, Ljungman P, Averbuch D, Cesaro S, de la Camara R, Baldomero H, Bader P, Basak G, Bonini C, Duarte R, Dufour C, Kuball J, Lankester A, Montoto S, Nagler A, Snowden JA, Kröger N, Mohty M, Gratwohl A; Infectious Diseases Working Party EBMT.

Bone Marrow Transplant. 2020 Jan;55(1):126-136. doi: 10.1038/s41409-019-0624-z. Epub 2019 Aug 27.

40.

Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.

Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, Byrne M, Jacoby E, Lazaryan A, Jacobson CA, Ansell SM, Awan FT, Burns L, Bachanova V, Bollard CM, Carpenter PA, DiPersio JF, Hamadani M, Heslop HE, Hill JA, Komanduri KV, Kovitz CA, Lazarus HM, Serrette JM, Mohty M, Miklos D, Nagler A, Pavletic SZ, Savani BN, Schuster SJ, Kharfan-Dabaja MA, Perales MA, Lin Y.

Biol Blood Marrow Transplant. 2019 Dec;25(12):2305-2321. doi: 10.1016/j.bbmt.2019.08.015. Epub 2019 Aug 22. Review.

PMID:
31446199
41.

Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy.

DeFilipp Z, Advani AS, Bachanova V, Cassaday RD, Deangelo DJ, Kebriaei P, Rowe JM, Seftel MD, Stock W, Tallman MS, Fanning S, Inamoto Y, Kansagra A, Johnston L, Nagler A, Sauter CS, Savani BN, Perales MA, Carpenter PA, Larson RA, Weisdorf D.

Biol Blood Marrow Transplant. 2019 Nov;25(11):2113-2123. doi: 10.1016/j.bbmt.2019.08.014. Epub 2019 Aug 22. Review.

PMID:
31446198
42.

Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Halaburda K, Labopin M, Mailhol A, Socié G, Craddock C, Aljurf M, Beelen D, Cornelissen JJ, Bourhis JH, Labussière-Wallet H, Blaise D, Gedde-Dahl T, Gilleece M, Yakoub-Agha I, Mufti G, Esteve J, Mohty M, Nagler A.

Haematologica. 2019 Aug 22. pii: haematol.2019.222810. doi: 10.3324/haematol.2019.222810. [Epub ahead of print]

43.

Personalizing rabbit anti-thymocyte globulin therapy for prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation: is there an optimal dose?

Shichijo T, Fuji S, Nagler A, Bazarbachi A, Mohty M, Savani BN.

Bone Marrow Transplant. 2019 Aug 21. doi: 10.1038/s41409-019-0643-9. [Epub ahead of print] Review.

PMID:
31435032
44.

Haploidentical stem cell transplantation (HaploSCT) for patients with acute leukemia-an update on behalf of the ALWP of the EBMT.

Nagler A, Ruggeri A.

Bone Marrow Transplant. 2019 Aug;54(Suppl 2):713-718. doi: 10.1038/s41409-019-0610-5.

PMID:
31431696
45.

Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT.

Shem-Tov N, Peczynski C, Labopin M, Itälä-Remes M, Blaise D, Labussière-Wallet H, Socié G, Kröger N, Mielke S, Afanasyev B, Chevallier P, Tischer J, Helbig G, Jindra P, Peric Z, Giebel S, Mohty M, Nagler A.

Leukemia. 2020 Jan;34(1):283-292. doi: 10.1038/s41375-019-0544-3. Epub 2019 Aug 19.

PMID:
31427719
46.

Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin.

Baron F, Galimard JE, Labopin M, Yakoub-Agha I, Niittyvuopio R, Kröger N, Griskevicius L, Wu D, Forcade E, Richard C, Aljurf M, Helbig G, Labussière-Wallet H, Mohty M, Nagler A.

Haematologica. 2019 Aug 14. pii: haematol.2019.227603. doi: 10.3324/haematol.2019.227603. [Epub ahead of print]

47.

Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study.

Kanda J, Hayashi H, Ruggeri A, Kimura F, Volt F, Takahashi S, Labopin M, Kako S, Tozatto-Maio K, Yano S, Sanz G, Uchida N, Van Lint MT, Kato S, Mohty M, Forcade E, Kanamori H, Sierra J, Ohno Y, Saccardi R, Fukuda T, Ichinohe T, Takanashi M, Rocha V, Okamoto S, Nagler A, Atsuta Y, Gluckman E.

Leukemia. 2020 Jan;34(1):128-137. doi: 10.1038/s41375-019-0534-5. Epub 2019 Aug 14.

PMID:
31409921
48.

Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

Giebel S, Boumendil A, Labopin M, Seesaghur A, Baron F, Ciceri F, Esteve J, Gorin NC, Savani B, Schmid C, Wetten S, Mohty M, Nagler A.

Ann Hematol. 2019 Oct;98(10):2389-2398. doi: 10.1007/s00277-019-03771-2. Epub 2019 Aug 7.

49.

Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT.

Gilleece MH, Labopin M, Savani BN, Yakoub-Agha I, Socié G, Gedde-Dahl T, Blaise D, Byrne JL, Craddock C, Cornelissen JJ, Arcese W, Forcade E, Crawley C, Polge E, Mohty M, Nagler A.

Leukemia. 2020 Jan;34(1):87-99. doi: 10.1038/s41375-019-0527-4. Epub 2019 Jul 30.

PMID:
31363160
50.

Risk factors and implications of oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation.

Shouval R, Kouniavski E, Fein J, Danylesko I, Shem-Tov N, Geva M, Yerushalmi R, Shimoni A, Nagler A.

Eur J Haematol. 2019 Oct;103(4):402-409. doi: 10.1111/ejh.13299. Epub 2019 Aug 12.

PMID:
31332836

Supplemental Content

Loading ...
Support Center